These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33334176)

  • 1. A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer.
    Roth JA; Yuan Y; Othus M; Danese M; Wagner S; Penrod JR; Ramsey SD
    J Med Econ; 2021; 24(1):79-86. PubMed ID: 33334176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
    Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR
    J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
    Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
    J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer.
    Smare C; Dave K; Juarez-Garcia A; Abraham P; Penrod JR; Camidge DR; Yuan Y
    J Med Econ; 2021; 24(1):1124-1133. PubMed ID: 34465261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
    Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
    Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
    Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
    J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
    Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
    JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
    Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
    J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
    [No Abstract]   [Full Text] [Related]  

  • 9. Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis.
    Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
    Clin Drug Investig; 2020 Feb; 40(2):129-137. PubMed ID: 31679121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US.
    Wang Y; Rui M; Yang L; Wang X; Shang Y; Ma A; Li H
    Front Public Health; 2021; 9():650392. PubMed ID: 33889559
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Tringale KR; Carroll KT; Zakeri K; Sacco AG; Barnachea L; Murphy JD
    J Natl Cancer Inst; 2018 May; 110(5):479-485. PubMed ID: 29126314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data.
    Chaudhary MA; Holmberg C; Lakhdari K; Smare C; Theriou C; Dale P; Penrod JR
    J Med Econ; 2021; 24(1):607-619. PubMed ID: 33870833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
    Marine S; Stéphane R; Nicolas P; Felizzi F; Paracha N; Benjamin M; Perol M
    J Med Econ; 2020 May; 23(5):464-473. PubMed ID: 31951770
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.
    Brodtkorb TH; Knight C; Kamgar F; Teitsson S; Kurt M; Patel MY; Poretta T; Mamtani R; Palmer S
    J Med Econ; 2024; 27(1):543-553. PubMed ID: 38470512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of nivolumab in patients with NSCLC in the United States.
    Chaudhary MA; Lubinga SJ; Smare C; Hertel N; Penrod JR
    Am J Manag Care; 2021 Aug; 27(8):e254-e260. PubMed ID: 34460179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
    Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
    Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
    J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
    Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
    Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China.
    Fei Z; Rui M; Wang Y; Ma A
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):79-87. PubMed ID: 36333963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
    Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
    Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.